Endogenous retroviruses and response to immune checkpoint inhibitors: mechanisms, clinical evidence, and therapeutic implications - Top-Institutions - MDSpire

Endogenous retroviruses and response to immune checkpoint inhibitors: mechanisms, clinical evidence, and therapeutic implications

  • By

  • Fanyuan Wu

  • Quezhu Danzeng

  • Runxi Wu

  • Yi Shen

  • Guang Shi

  • May 20, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    The University of Texas MD Anderson Cancer Center
    The University of Texas MD Anderson Cancer Center

    Houston, Texas

    Key Differentiators

    • Oncology
    • Immunotherapy

  • #2

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, New York

    Key Differentiators

    • Oncology
    • Immunotherapy

  • #3

    The Ohio State University Comprehensive Cancer Center
    The Ohio State University Comprehensive Cancer Center

    Columbus, Ohio

    Key Differentiators

    • Oncology

  • #4

    Rockefeller University
    Rockefeller University

    New York, New York

    Key Differentiators

    • Oncology
    • Molecular Biology

  • #5

    Vanderbilt-Ingram Cancer Center
    Vanderbilt-Ingram Cancer Center

    Nashville, Tennessee

    Key Differentiators

    • Oncology

Original Source(s)

Endogenous retroviruses and response to immune checkpoint inhibitors: mechanisms, clinical evidence, and therapeutic implications

  • by Fanyuan Wu, Quezhu Danzeng, Runxi Wu, Yi Shen, Guang Shi

  • May 20, 2026

Related Content

Potential targets for boron transport in boron neutron capture therapy

Trametinib as second-line therapy for advanced KRAS G12C-mutant non-small cell lung cancer: a single-center clinical analysis of 20 cases

Ultra-high-sensitivity next-generation sequencing–based MRD predicts outcome in intensively treated older patients with acute myeloid leukemia: results from the ALFA-1200 cohort